|
Bafutto et al., 2011
|
61 (18:43)
|
cohort
|
Rome III with IBS-D, as reported by patient
|
- Mesalazine
|
30 days
|
- stool frequency decreased by 1.33 stools/day on average
|
Moderate
|
|
- 30 days
|
The study is unclear as to how the randomization and allocation concealment were conducted.
|
|
- 800 mg
|
|
- TID
|
|
- stool form and consistency improved by 2.17 based on the Bristol stool scale (16)
|
|
Hanevik et al., 2011
|
18 (11:7)
|
RCT
|
History of giardiasis 2 years prior and Rome II criteria
|
- Mesalazine
|
6 weeks
|
- no significant change in symptoms following mesalazine treatment
|
Low
|
|
- 6 weeks
|
The study was a pilot study with small sample. It is unclear as to how to randomization and allocation concealment were conducted
|
|
- 800 mg
|
|
- BID
|
|
Tuteja et al., 2012
|
20 (10:10)
|
RCT
|
Onset of IBS symptoms in previously asymptomatic individuals after acute gastroenteritis characterized by two or more of: diarrhea, vomiting, fever, as reported by the patient
|
- Mesalamine
|
12 weeks
|
- no significant change in symptoms following mesalazine treatment
|
Low
|
|
- 12 weeks
|
Insufficient sample size
|
|
- 1.6 g
|
|
- BID
|
|
Dizdar et al., 2007
|
34 (15:39)
|
RCT
|
Persisting abdominal symptoms 12 months after Giardia infection and Rome II criteria, as reported by Giardia outpatient clinic
|
- Ondansetron
|
2 days
|
- no significant improvement in symptoms after ondansetron treatment - Significant improvement in post-prandial nausea score before vs after ondanestron treatment (27.47 ± 21.89 vs 41.40 ± 23.04)
|
Moderate
|
|
- 2 days
|
Small sample size
|
|
- 8 mg
|
|
- QD
|
|
Dunlop et al., 2003
|
34 (20:14)
|
RCT
|
New bowel symptoms in a previously asymptomatic individuals immediately after an acute illness characterized by two or more of: diarrhea, fever, vomiting, positive stool culture, as recorded by the patient or gastroenterology clinic
|
- Prednisone
|
21 days
|
- No improvement in abdominal pain, diarrhea, frequency or urgency based on a gastrointestinal symptom rating scale
|
Moderate
|
|
- 21 days
|
Small sample size
|
|
- 30 mg
|
|
- QD
|
|
Menon et al., 2011
|
25 (15:10)
|
Retrospective
|
History of an acute gastroenteritis precipitating chronic diarrhea, as reported in clinic notes and hospital database
|
- Cholestyramine
|
Variable (1–15 years)
|
- decrease in diarrhea frequency of 5.9 stools/day
|
Low
|
|
- 1–15 years
|
Retrospective study that only included people with bile acid malabsorption and infectious gastroenteritis.
|
|
- 8.22 g
|
|
- QD
|
|
Niaz et al., 1997
|
16 (16:0)
|
Retrospective
|
History of an acute gastroenteritis precipitating chronic diarrhea defined as distinct change in bowel habit with 4–15 loose watery motions per day as reported by the patient
|
- Cholestyramine
|
2 weeks
|
- decreased stool frequency of 5.1 stools/day
|
Low
|
|
- 2 weeks
|
Retrospective study that only included people with bile acid malabsorption and infectious gastroenteritis.
|
|
- 2–16 g
|
|
- QD
|
|
Thakur et al., 2009
|
76 (17:59)
|
RCT
|
Rome II criteria and history of gastroenteritis or dysentery as reported by the patient
|
-Metronidazole
|
7 days
|
- improvement in pain, stool and total symptom scores at days 7 and 28
|
Low
|
|
Study was not randomized, and both patient and physician were not blinded. 9 patients were lost to follow-up but it is unclear if they were included in analysis.
|
|
- 4 weeks
|
|
- 400 mg
|
|
- TID
|
|
- stool symptoms continued to improve between day 7 and 28 even though patients were no longer taking the medication
|
|
Lifshitz et al., 1990
|
29 (10:19)
|
RCT
|
History of chronic diarrhea after an episode of gastroenteritis lasting more than 3 weeks as reported by Pediatric Gastroenterology unit
|
- Pregestimil
|
variable
|
- 9 out of 10 infants had improved clinical symptoms, shorter time to improvement
|
Moderate
|
|
- 3 – 7 days
|
Population was limited to infants with lactose intolerance. Inclusion was based on chronic diarrhea, not on established criteria such as Rome criteria.
|
|
- 1500 mL/kg
|
|
- Daily to provide 70 kcal/kg
|
